Literature DB >> 15837793

The IkappaB kinase is a key factor in triggering influenza A virus-induced inflammatory cytokine production in airway epithelial cells.

Daniela Bernasconi1, Carla Amici, Simone La Frazia, Angela Ianaro, M Gabriella Santoro.   

Abstract

Influenza A viruses continue to represent a severe threat worldwide, causing large epidemics and pandemics responsible for thousands of deaths every year. Excessive inflammation due to overabundant production of proinflammatory cytokines by airway epithelial cells is considered an important factor in disease pathogenesis. Here we report that influenza A virus induced IkappaB kinase (IKK) activity in human airway epithelial A549 cells, resulting in persistent activation of nuclear factor-kappaB (NF-kappaB), a critical regulator of the inflammatory response. Although lung epithelial cells are highly sensitive to stimulation of the IKK/NF-kappaB pathway by influenza virus infection, NF-kappaB was not activated in several non-pulmonary cells permissive to the virus, indicating a cell-specific response. Moreover, NF-kappaB was not essential for virus replication but triggered the expression of proinflammatory cytokines in infected lung cells and was directly responsible for production of high levels of interleukin-8, a chemokine associated with influenza-induced inflammation and airway pathology. We also report that 9-deoxy-delta9,delta12-13,14-dihydro-prostaglandin D2, a cyclopentenone prostanoid with therapeutic efficacy against influenza in preclinical studies, was a powerful inhibitor of influenza virus-induced IKK activity and interleukin-8 production by human pulmonary cells. The results identify IKK as an important factor in triggering influenza virus-induced inflammatory reactions in pulmonary epithelium, suggesting novel therapeutic approaches in the treatment of influenza.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15837793     DOI: 10.1074/jbc.M413726200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  Inhibition of type I interferon production via suppressing IKK-gamma expression: a new strategy for counteracting host antiviral defense by influenza A viruses?

Authors:  Yimeng Wang; Jianhong Zhou; Chuanmin Ruan; Yuchun Du
Journal:  J Proteome Res       Date:  2011-11-29       Impact factor: 4.466

2.  Plasticity and virus specificity of the airway epithelial cell immune response during respiratory virus infection.

Authors:  Ioannis Ioannidis; Beth McNally; Meredith Willette; Mark E Peeples; Damien Chaussabel; Joan E Durbin; Octavio Ramilo; Asuncion Mejias; Emilio Flaño
Journal:  J Virol       Date:  2012-03-07       Impact factor: 5.103

3.  Synergistic effect of nitazoxanide with neuraminidase inhibitors against influenza A viruses in vitro.

Authors:  Giuseppe Belardo; Orlando Cenciarelli; Simone La Frazia; Jean Francois Rossignol; M Gabriella Santoro
Journal:  Antimicrob Agents Chemother       Date:  2014-12-01       Impact factor: 5.191

4.  Verdinexor, a novel selective inhibitor of nuclear export, reduces influenza a virus replication in vitro and in vivo.

Authors:  Olivia Perwitasari; Scott Johnson; Xiuzhen Yan; Elizabeth Howerth; Sharon Shacham; Yosef Landesman; Erkan Baloglu; Dilara McCauley; Sharon Tamir; S Mark Tompkins; Ralph A Tripp
Journal:  J Virol       Date:  2014-06-25       Impact factor: 5.103

5.  Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level.

Authors:  Jean François Rossignol; Simone La Frazia; Lucia Chiappa; Alessandra Ciucci; M Gabriella Santoro
Journal:  J Biol Chem       Date:  2009-07-28       Impact factor: 5.157

6.  Innate immunity to influenza virus: implications for future therapy.

Authors:  Mitchell R White; Mona Doss; Patrick Boland; Tesfaldet Tecle; Kevan L Hartshorn
Journal:  Expert Rev Clin Immunol       Date:  2008-07-01       Impact factor: 4.473

7.  Mitogen-activated protein kinase-activated kinase RSK2 plays a role in innate immune responses to influenza virus infection.

Authors:  Satoshi Kakugawa; Masayuki Shimojima; Hideo Goto; Taisuke Horimoto; Naoki Oshimori; Gabriele Neumann; Tadashi Yamamoto; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2009-01-07       Impact factor: 5.103

8.  Anti-inflammatory effect of thalidomide on H1N1 influenza virus-induced pulmonary injury in mice.

Authors:  Haiyan Zhu; Xunlong Shi; Dianwen Ju; Hai Huang; Wei Wei; Xiaoying Dong
Journal:  Inflammation       Date:  2014-12       Impact factor: 4.092

9.  Involvement of the Akt/NF-κB pathways in the HTNV-mediated increase of IL-6, CCL5, ICAM-1, and VCAM-1 in HUVECs.

Authors:  Haitao Yu; Wei Jiang; Hong Du; Yuan Xing; Guangzhen Bai; Ye Zhang; Yu Li; Hong Jiang; Ying Zhang; Jiuping Wang; Pingzhong Wang; Xuefan Bai
Journal:  PLoS One       Date:  2014-04-08       Impact factor: 3.240

10.  Early activation of MAP kinases by influenza A virus X-31 in murine macrophage cell lines.

Authors:  Georgetta Cannon; Michelle A Callahan; Jenny Q Gronemus; R Joel Lowy
Journal:  PLoS One       Date:  2014-08-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.